[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mmr-vaccine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mmr-vaccine":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100586798","phase-4-study-of-concomitant-administration-of-the-sipv-and-dtap-or-mmr-100586798",false,"NCT06920069","Study of Concomitant Administration of the sIPV and DTaP or MMR","Phase IV Study of Evaluating Immunogenicity and Safety of Concomitant Administration of Sabin-strain-based Inactivated Poliovirus Vaccine (Vero Cells) and Adsorbed Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine or Measles, Mumps and Rubella Combined Live-attenuated Vaccine","Inclusion Criteria:\n\n* Age Requirement: Infants aged 2 months at the time of enrollment\n* Provision of Legal Identification: Volunteers and their legal guardians or appointed representatives must provide valid legal identification documents.\n* Informed Consent: Legal guardians or appointed representatives of volunteers must have the capacity to understand the informed consent document and the research process, voluntarily participate, and sign the informed consent form.\n* Adherence: Legal guardians or appointed representatives of volunteers must be able to comply with the requirements in the study as well as complete relevant visits on time.\n* Birth Condition: Full-term at birth (gestational age ≥ 37 weeks and \\\u003C 42 weeks) and birth weight ≥ 2500g\n\nExclusion Criteria:\n\n* Vaccination History: received vaccines containing diphtheria-tetanus-pertussis antigens, polio antigens, Hib conjugate vaccine, or 13-valent pneumococcal conjugate vaccine before enrollment.\n* Those who had received blood transfusions or used blood products (except hepatitis B immunoglobulin) before enrollment.\n* Recent Vaccination: Volunteers received any inactivated vaccines or subunit vaccines within 7 days (including the 7th day) prior to vaccination with the investigational vaccine, or any other live attenuated vaccines within 14 days (including the 14th day) prior to vaccination.\n* Acute Illness: Volunteers have experienced acute illnesses (e.g., fever) within 3 days before enrollment, or have used antipyretic analgesics or antihistamines within 3 days.\n* Allergic History: Volunteers who are allergic to any component of sIPV, bOPV, DTaP, or MMR, or who are allergic to kanamycin sulfate, kanamycin, or gentamicin sulfate, or those with an allergic constitution.\n* Birth Condition: Severe neonatal diseases caused by abnormal delivery and other reasons, such as birth trauma, neonatal asphyxia, respiratory distress syndrome, neonatal intracranial hemorrhage, etc., or patients with clinically confirmed severe hyperbilirubinemia.\n* Neurological and Mental Health: Volunteers with encephalopathy, convulsions, epilepsy, or other progressive neurological disorders, or those whose families have a history of genetic predisposition to convulsions or epilepsy, or a history of genetic predisposition to mental illness.\n* History of Related Illness: Volunteers who have a history of poliomyelitis, pertussis, diphtheria, tetanus, measles, rubella, or mumps.\n* Immune Therapy: Volunteers with immunodeficiency, weakened immune function, or those who have received immunosuppressive therapy (such as long-term systemic glucocorticoid treatment, but excluding local medications like inhalants or nasal sprays).\n* Other Diseases: Volunteers with severe diseases, encompassing those in the cardiovascular system, blood and lymphatic systems, immune system, kidneys, liver, gastrointestinal tract, respiratory system, metabolism, and bones, etc.\n* Participation in Other Clinical Studies: Volunteers are currently or have plans to participate in other clinical studies before enrollment.\n* Investigator's Discretion: The final exclusion criterion is the investigator's discretion to determine whether a volunteer is suitable for participation in the study.",true,"ALL","2 Months",{"count":20,"type":21},2640,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months. Primary immunogenicity endpoints in all groups include the seroconversion rate of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies 30 days after basic immunization. Secondary immunogenicity endpoints include the seropositive rates, seroconversion rates, geometric mean titer\u002Fconcentration (GMT\u002FGMC), geometric mean fold increase (GMFI) of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies 30 days after full immunization. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.",[27,28,29],"Polio","Diphteria, Tetanus and Pertussis","MMR Vaccine","NOT_YET_RECRUITING","2025-04-14",{"date":33,"type":34},"2025-04-17","ACTUAL",{"date":36,"type":21},"2025-05-15",{"date":38,"type":21},"2031-06-15",{"name":40,"class":41},"Institute of Medical Biology, Chinese Academy of Medical Sciences","OTHER",9,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100584632","phase-4-study-of-live-attenuated-varicella-vaccine-co-administered-with-mmr-vaccine-or-dtap-vaccine-100584632","NCT06891872","Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","Immunogenicity and Safety of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine in Healthy Children Aged 18~24 Months: an Open-label, Randomized, Phase Ⅳ Study Clinical Trial","Inclusion Criteria:\n\n* Infants aged 18-24 months;\n* have completed 3 doses of DTaP for primary immunization in their first year of life without the fourth dose of Dtap-containing vaccine;\n* have completed the first dose of MMR in their first year of life without a second dose of MMR;\n* Guardians of participants who are able to understand and voluntarily sign informed consent;\n* Provision of legal proof of identity.\n\nExclusion Criteria:\n\n* Having a history of previous varicella vaccination;\n* Having a history of chickenpox, pertussis, diphtheria, tetanus, measles, mumps, and rubella;\n* Having a history of uncontrolled chronic or serious diseases, including but not limited to cardiovascular diseases, hematological diseases, liver and kidney diseases, digestive diseases, respiratory diseases, malignant tumors, major functional organ transplantation, etc.;\n* Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n* Presence of abnormal coagulation function (e.g. coagulation factor deficiency, platelet abnormality);\n* Having\u002FPrevious having a severe neurological disorder (epilepsy, seizures, or convulsions) or psychosis, or have a family history of psychosis;\n* Acute onset of various acute or chronic illnesses within the last 7 days, or known or suspected active infection;\n* Receipt of \\> 14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥2 mg\u002Fkg\u002F day or its equivalent, except topical or inhaled corticosteroids), cytotoxic therapy within the past 6 months, or planned to receive such therapy during the trial;\n* Having received immune globulin or other blood products within the past 3 months or plan to receive such treatment during the trial;\n* Receipt of another study drug or vaccine within the past 30 days or plans to receive such drug or vaccine during the trial;\n* Administration of live attenuated vaccine within the past 28 days or subunit, inactivated, or other process vaccine within the past 7 days;\n* Known allergies to the vaccine or vaccine components, such as urticaria after vaccination, dyspnea, angioedema;\n* Having fever on the day of scheduled vaccination (axillary temperature \\> 37.0 ° C);\n* Failure of medical examination on the planned vaccination day;\n* Participants have any other factors that, in the judgment of the investigator, make them ineligible to participate in a clinical trial.","18 Months","24 Months",{"count":53,"type":21},720,[24],"This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella vaccine co-administered with MMR vaccine or DTaP vaccine. The secondary objective is to evaluate the safety of the vaccines when administered simultaneously.",[57,29,58],"Varicella (chickenpox)","DTaP Vaccine",[60,61],"Co-administered","VZV","2025-03-17",{"date":64,"type":34},"2025-03-24",{"date":66,"type":21},"2025-05",{"date":68,"type":21},"2025-12",{"name":70,"class":71},"Sinovac (Dalian) Vaccine Technology Co., Ltd.","INDUSTRY",1]